Emily Lemke - Concepedia

Author

Emily Lemke

The University of Texas MD Anderson Cancer Center

Also Known As

E Lemke, E. Lemke, E.A. Lemke, Emily A Lemke, Emily A. Lemke, Emily A. Lemke, DNP, AGPCNP-BC, AOCNP, Emily A. Lemke, DNP, RN, AGPCNP-BC, AOCNP, Emily Lemke, Emily Lemke, DNP, AGPCNP-BC, AOCNP

Publications

388

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center UCSF Helen Diller Family Comprehensive Cancer Center Memorial Sloan Kettering Cancer Center University of California, San Francisco University of Washington

About

Emily Lemke is an author at The University of Texas MD Anderson Cancer Center specializing in cancer therapeutics, urology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	211
2	Cancer Therapeutics	4	4	211
3	Surgical Oncology	2	2	75
4	Health Sciences	1	1	16
5	Diagnostic Sciences	1	1	16

Emily Lemke

Publications

314

Citations

H-Index

Page 1

	Year	Citations
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors Amishi Y. Shah, Ritesh R. Kotecha, Emily Lemke, European Journal of Cancer UrologyGenitourinary CancerMedicineImmune Checkpoint InhibitorCancer Treatment	2019	120
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study Vadim S. Koshkin, Nicholas Henderson, Marihella James, Cancer	2021	80
Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis Matthew T. Campbell, Mehmet Asım Bilen, Amishi Y. Shah, European Journal of Cancer UrologySurgical OncologyOncologyGenitourinary CancerRetrospective Analysis	2018	64
Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study. Amanda Nizam, Tanya Jindal, Cindy Jiang, Journal of Clinical Oncology Cancer ManagementClinical EndpointMedian TimePharmacotherapyGynecology Oncology	2024	16
Outcomes of patients with metastatic clear cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Amishi Y. Shah, Ritesh R. Kotecha, Emily Lemke, Journal of Clinical Oncology	2019	13
Management of Advanced Bladder Cancer: An Update Emily Lemke, Amishi Y. Shah Journal of the Advanced Practitioner in Oncology Urological ResearchUrologySurgical OncologyAdvanced Bladder CancerGenitourinary Cancer	2018	11
Current and Future Landscape of Immune Checkpoint Inhibitors in Urothelial Cancer. Omar Alhalabi, Amishi Y. Shah, Emily Lemke, PubMed	2019	10

Page 1